移植向けHLAタイピングの世界市場：技術別、製品別、用途別、タイプ別、エンドユーザー別 - 予測（～2030年）

世界の移植向けHLAタイピングの市場規模は、2025年の11億米ドルから2030年までに14億米ドルに達すると予測され、予測期間にCAGRで6.0%の成長が見込まれます。

HLAタイピング市場の成長は、先進のHLAタイピング技術の開発、臓器移植需要の高まり、臓器提供率の向上を目指した政府の戦略的取り組み、HLAタイピング手法に焦点を当てた研究活動の拡大などの複数の要因によって推進されています。

技術別では、分子アッセイセグメントが2024年に最大の市場シェアを占めました。

2024年、分子アッセイ技術セグメントが移植向けHLAタイピング市場を独占しました。これはエンドユーザーの間で分子アプローチを利用する動向が顕著であることを反映しています。この優位性は、メーカー各社が分子プラットフォーム内の高分解能アッセイを進歩させることを重視し、移植向けHLAタイピングの精度と信頼性を高めていることによるものです。

エンドユーザー別では、独立系リファレンスラボラトリーセグメントが2024年に最大の市場シェアを占めました。

2024年、独立系リファレンスラボラトリーが市場を独占すると予測されます。これは、診断ラボの間でHLAタイピングサービスをバイオテクノロジー企業に委託する動向が強まっていることによるものです。このシフトは、高分解能分子技術の登場と、リファレンスラボラトリーと移植センター間の戦略的パートナーシップの増加によって促進され、サービスの効率と診断精度を高めています。

地域別では、北米が2024年に最大の市場シェアを占めました。

2024年、北米が移植向けHLAタイピング市場を独占し、欧州が僅差でこれに続きました。この動向は、最先端の診断技術の利用可能性、メーカーの強固なエコシステム、確立された医療インフラなどの複数の要因によるものと考えられます。さらに、この地域には新規HLA対立遺伝子の研究開発に積極的な主要バイオテクノロジー企業があります。移植率の上昇や支援的な償還枠組みもあり、これらの要素が北米での市場の拡大に大きく寄与しています。

当レポートでは、世界の移植向けHLAタイピング市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主な調査結果

• 移植市場の概要
• 北米の移植向けHLAタイピング市場：製品・サービス別、国別（2024年）
• 移植向けHLAタイピング市場：新興市場と先進市場（2025年・2030年）
• 移植向けHLAタイピング市場：地理的成長機会

第5章 市場の概要

• イントロダクション
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
• 規制分析
  • 規制枠組み
  • 規制機関、政府機関、その他の組織
• バリューチェーン分析
  • 研究開発
  • 原材料調達と製品開発
  • マーケティング、販売、流通、アフターマーケットサービス
• サプライチェーン分析
  • 著名企業
  • 中小企業
  • 販売業者
  • エンドユーザー
• エコシステム分析
• 貿易分析
  • HSコード3822の輸入シナリオ（2020年～2024年）
  • HSコード3822の輸出シナリオ（2020年～2024年）
• 特許分析
• 価格分析
  • 器具の平均販売価格の動向：タイプ別（2023年～2024年）
  • 次世代シーケンシング器具の平均販売価格の動向：主要企業別（2023年～2024年）
  • 試薬の平均販売価格の動向：タイプ別（2022年～2024年）
• 技術分析
  • 主要技術
  • 補完技術
  • 隣接技術
• ポーターのファイブフォース分析
• 主なステークホルダーと購入基準
• 主な会議とイベント（2024年～2025年）
• ケーススタディ分析
• 顧客のビジネスに影響を与える動向/混乱
• 投資と資金調達のシナリオ
• アンメットニーズ
• 移植向けHLAタイピング市場に対するAI/生成AIの影響
  • 移植前評価向けHLAタイピング製品の市場可能性
  • 移植向けHLAタイピング市場におけるAIの将来
• 移植向けHLAタイピング市場に対する2025年の米国関税の影響
  • イントロダクション
  • 主な関税率
  • 価格の影響の分析
  • 国/地域に対する影響
  • 最終用途産業に対する影響

第6章 移植向けHLAタイピング市場：製品・サービス別

• イントロダクション
• 試薬・消耗品
• 器具
• ソフトウェア・サービス

第7章 移植向けHLAタイピング市場：技術別

• イントロダクション
• 分子アッセイ
• シーケンシングに基づく分子アッセイ
  • サンガーシーケンシング
  • 次世代シーケンシング
  • その他のシーケンシングに基づく分子アッセイ
• 非分子アッセイ

第8章 移植向けHLAタイピング市場：用途別

• イントロダクション
• 診断用途
  • 抗体スクリーニング
  • キメリズムモニタリング
  • その他の診断用途
• 研究用途

第9章 移植向けHLAタイピング市場：移植タイプ別

• イントロダクション
• 固形臓器移植
• 軟部組織移植
• 幹細胞移植

第10章 移植向けHLAタイピング市場：エンドユーザー別

• イントロダクション
• 独立系リファレンスラボラトリー
• 病院・移植センター
• 研究所・学術機関

第11章 移植向けHLAタイピング市場：地域別

• イントロダクション
• 北米
  • 北米のマクロ経済の見通し
  • 米国
  • カナダ
• 欧州
  • 欧州のマクロ経済の見通し
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他の欧州
• アジア太平洋
  • アジア太平洋のマクロ経済の見通し
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ラテンアメリカのマクロ経済の見通し
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
• 中東・アフリカ
  • 中東・アフリカのマクロ経済の見通し
  • GCC諸国
  • その他の中東・アフリカ

第12章 競合情勢

• イントロダクション
• 主要参入企業の戦略/強み
• 収益分析（2020年～2024年）
• 市場シェア分析（2024年）
• 企業の評価マトリクス：主要企業（2024年）
• 企業の評価マトリクス：スタートアップ/中小企業（2024年）
• 企業の評価と財務指標
  • 財務指標
  • 企業の評価
• ブランド/製品の比較
• 競合シナリオ

第13章 企業プロファイル

• 主要企業
  • THERMO FISHER SCIENTIFIC INC.
  • ILLUMINA, INC.
  • QIAGEN
  • BIO-RAD LABORATORIES, INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • CAREDX, INC.
  • WERFEN
  • DIASORIN S.P.A.
  • TBG BIOTECHNOLOGY CORP.
  • FUJIREBIO
  • BECTON, DICKINSON AND COMPANY
  • EUROBIO SCIENTIFIC
  • PACBIO
  • BAG DIAGNOSTICS GMBH
  • CREATIVE BIOLABS
• その他の企業
  • HISTOGENETICS LLC
  • SCISCO GENETICS, INC.
  • INNO-TRAIN DIAGNOSTIK GMBH
  • BIONOBIS
  • TAKARA BIO INC.
  • KRISHGEN BIOSYSTEMS
  • SCIENCELL RESEARCH LABORATORIES, INC.
  • PROIMMUNE LTD.
  • ALPHA BIOTECH LIMITED
  • BIOFORTUNA LIMITED

第14章 付録

List of Tables

• TABLE 1 HLA TYPING FOR TRANSPLANT MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 HLA TYPING FOR TRANSPLANT MARKET ASSUMPTIONS
• TABLE 3 HLA TYPING FOR TRANSPLANT MARKET: RISK ANALYSIS
• TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 8 HLA TYPING MARKET: ROLE IN ECOSYSTEM
• TABLE 9 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020-2024 (USD THOUSAND)
• TABLE 10 HLA TYPING FOR TRANSPLANT MARKET: EXPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020-2024 (USD THOUSAND)
• TABLE 11 HLA TYPING FOR TRANSPLANT MARKET: LIST OF MAJOR PATENTS/ PATENT APPLICATIONS
• TABLE 12 AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023-2024 (USD)
• TABLE 13 AVERAGE SELLING PRICING TREND OF INSTRUMENTS AND REAGENTS, BY REGION, 2022-2024 (USD THOUSAND)
• TABLE 14 HLA TYPING FOR TRANSPLANT MARKET: PORTERS FIVE FORCES
• TABLE 15 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
• TABLE 16 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR MAJOR END USERS
• TABLE 17 HLA TYPING FOR TRANSPLANT MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
• TABLE 18 THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING HLA TYPING ACCURACY IN TRANSPLANTATION
• TABLE 19 ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION
• TABLE 20 WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING
• TABLE 21 HLA TYPING FOR TRANSPLANT MARKET: UNMET NEEDS
• TABLE 22 HLA TYPING FOR TRANSPLANT MARKET: KEY COMPANIES IMPLEMENTING AI
• TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 24 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 25 HLA TYPING FOR TRANSPLANT MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 26 HLA TYPING FOR TRANSPLANT MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 27 HLA TYPING FOR TRANSPLANT MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 28 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 29 HLA TYPING FOR TRANSPLANT TECHNOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 30 HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 31 HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 32 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 33 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 34 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 35 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 36 REAL-TIME PCR MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 37 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 38 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 39 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 40 SANGER SEQUENCING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 41 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 42 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 43 HLA TYPING FOR TRANSPLANT MARKET FOR NON-MOLECULAR ASSAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 44 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 45 HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 46 HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 47 ANTIBODY SCREENING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 48 CHIMERISM MONITORING MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 49 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 50 HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 51 HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2023-2030 (USD MILLION)
• TABLE 52 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 53 HLA TYPING FOR SOFT-TISSUE TRANSPLANTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 54 HLA TYPING FOR STEM CELL TRANSPLANTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 55 HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 56 HLA TYPING FOR TRANSPLANT MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2023-2030 (USD MILLION)
• TABLE 57 HLA TYPING FOR TRANSPLANT MARKET FOR HOSPITALS & TRANSPLANT CENTERS, 2023-2030 (USD MILLION)
• TABLE 58 HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2023-2030 (USD MILLION)
• TABLE 59 HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 60 HLA TYPING FOR TRANSPLANT MARKET: TRANSPLANT VOLUME BY TYPE, 2023 (NUMBER OF TRANSPLANTS)
• TABLE 61 NORTH AMERICA: KEY MACROINDICATORS
• TABLE 62 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 64 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 65 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 66 US: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 67 US: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 68 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 69 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 70 CANADA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 71 CANADA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 72 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 73 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 74 EUROPE: KEY MACROINDICATORS
• TABLE 75 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 76 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 77 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 78 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 79 GERMANY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 80 GERMANY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 81 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 82 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 83 UK: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 84 UK: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 85 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 86 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 87 FRANCE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 88 FRANCE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 89 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 90 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 91 SPAIN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 92 SPAIN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 93 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 94 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 95 ITALY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 96 ITALY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 97 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 98 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 99 REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 100 REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 101 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 102 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 103 ASIA PACIFIC: KEY MACROINDICATORS
• TABLE 104 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 105 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 106 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 107 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 108 CHINA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 109 CHINA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 110 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 111 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 112 INDIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 113 INDIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 114 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 115 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 116 JAPAN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 117 JAPAN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 118 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 119 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 120 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 121 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 122 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 123 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 124 SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 125 SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 126 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 127 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 128 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 129 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 130 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 131 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 132 LATIN AMERICA: KEY MACROINDICATORS
• TABLE 133 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 135 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 136 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 137 BRAZIL: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 138 BRAZIL: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 139 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 140 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 141 MEXICO: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 142 MEXICO: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 143 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 144 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 145 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 146 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 147 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 148 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 149 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
• TABLE 150 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 151 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 152 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 153 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 154 GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 155 GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 156 GCC COUNTRIES: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 157 GCC COUNTRIES: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 158 REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 159 REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 160 REST OF MIDDLE EAST & AFRICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 161 REST OF MIDDLE EAST & AFRICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 162 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN HLA TYPING FOR TRANSPLANT MARKET
• TABLE 163 HLA TYPING FOR TRANSPLANT MARKET: DEGREE OF COMPETITION
• TABLE 164 HLA TYPING FOR TRANSPLANT MARKET: REGION FOOTPRINT
• TABLE 165 HLA TYPING FOR TRANSPLANT MARKET: PRODUCT & SERVICE FOOTPRINT
• TABLE 166 HLA TYPING FOR TRANSPLANT MARKET: TECHNOLOGY FOOTPRINT
• TABLE 167 HLA TYPING FOR TRANSPLANT MARKET: APPLICATION FOOTPRINT
• TABLE 168 HLA TYPING FOR TRANSPLANT MARKET: END-USER FOOTPRINT
• TABLE 169 HLA TYPING FOR TRANSPLANT MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
• TABLE 170 HLA TYPING FOR TRANSPLANT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT & SERVICE AND REGION
• TABLE 171 HLA TYPING FOR TRANSPLANT MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 172 HLA TYPING FOR TRANSPLANT MARKET: DEALS, JANUARY 2022-APRIL 2025
• TABLE 173 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 174 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 175 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 176 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 177 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 178 ILLUMINA, INC.: COMPANY OVERVIEW
• TABLE 179 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 180 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 181 QIAGEN: COMPANY OVERVIEW
• TABLE 182 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 183 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 184 QIAGEN: DEALS, JANUARY 2022-APRIL 2025
• TABLE 185 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 186 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 187 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 188 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 189 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 190 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 191 CAREDX, INC.: COMPANY OVERVIEW
• TABLE 192 CAREDX, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 193 CAREDX, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 194 CAREDX, INC.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 195 WERFEN: COMPANY OVERVIEW
• TABLE 196 WERFEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 197 WERFEN: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 198 WERFEN: DEALS, JANUARY 2022-APRIL 2025
• TABLE 199 DIASORIN S.P.A.: COMPANY OVERVIEW
• TABLE 200 DIASORIN S.P.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 201 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 202 TBG BIOTECHNOLOGY CORP.: COMPANY OVERVIEW
• TABLE 203 TBG BIOTECHNOLOGY CORP.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 204 TBG BIOTECHNOLOGY CORP.: PRODUCT APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 205 TBG BIOTECHNOLOGY CORP.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 206 FUJIREBIO: COMPANY OVERVIEW
• TABLE 207 FUJIREBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 208 FUJIREBIO: DEALS, JANUARY 2022-APRIL 2025
• TABLE 209 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
• TABLE 210 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 211 EUROBIO SCIENTIFIC: COMPANY OVERVIEW
• TABLE 212 EUROBIO SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 213 EUROBIO SCIENTIFIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 214 EUROBIO SCIENTIFIC: DEALS, JANUARY 2022-APRIL 2025
• TABLE 215 PACBIO: COMPANY OVERVIEW
• TABLE 216 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 217 PACBIO: PRODUCT APPROVALS AND UPDATES, JANUARY 2022-APRIL 2025
• TABLE 218 PACBIO: DEALS, JANUARY 2022-APRIL 2025
• TABLE 219 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
• TABLE 220 BAG DIAGNOSTICS GMBH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 221 CREATIVE BIOLABS: COMPANY OVERVIEW
• TABLE 222 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 223 HISTOGENETICS LLC: COMPANY OVERVIEW
• TABLE 224 SCISCO GENETICS, INC.: COMPANY OVERVIEW
• TABLE 225 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW
• TABLE 226 BIONOBIS: COMPANY OVERVIEW
• TABLE 227 TAKARA BIO INC.: COMPANY OVERVIEW
• TABLE 228 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW
• TABLE 229 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 230 PROIMMUNE LTD.: COMPANY OVERVIEW
• TABLE 231 ALPHA BIOTECH LIMITED: COMPANY OVERVIEW
• TABLE 232 BIOFORTUNA LIMITED: COMPANY OVERVIEW

List of Figures

• FIGURE 1 HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 HLA TYPING FOR TRANSPLANT MARKET: YEARS CONSIDERED
• FIGURE 3 HLA TYPING FOR TRANSPLANT MARKET: RESEARCH DESIGN
• FIGURE 4 HLA TYPING FOR TRANSPLANT MARKET: KEY PRIMARY SOURCES
• FIGURE 5 HLA TYPING FOR TRANSPLANT MARKET: KEY INSIGHTS FROM PRIMARIES
• FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
• FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 8 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
• FIGURE 9 MARKET SIZE ESTIMATION FOR HLA TYPING FOR TRANSPLANT MARKET: COMPANY REVENUE ESTIMATION
• FIGURE 10 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2024)
• FIGURE 11 HLA TYPING FOR TRANSPLANT MARKET: COMPANY REVENUE- AND PROCEDURE-BASED MARKET ESTIMATION APPROACH
• FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 13 HLA TYPING FOR TRANSPLANT MARKET: DATA TRIANGULATION
• FIGURE 14 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• FIGURE 16 HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 17 HLA TYPING FOR TRANSPLANT MARKET: REGIONAL SNAPSHOT
• FIGURE 18 IMPROVED HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET
• FIGURE 19 US AND REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
• FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
• FIGURE 21 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
• FIGURE 22 HLA TYPING FOR TRANSPLANT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 23 HLA TYPING FOR TRANSPLANT MARKET: VALUE CHAIN ANALYSIS
• FIGURE 24 HLA TYPING FOR TRANSPLANT MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 25 HLA TYPING FOR TRANSPLANT MARKET: ECOSYSTEM ANALYSIS
• FIGURE 26 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822 (2020-2024)
• FIGURE 27 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822 (2020-2024)
• FIGURE 28 HLA TYPING FOR TRANSPLANT MARKET: TOP PATENT APPLICANTS/ OWNERS (JANUARY 2014-DECEMBER 2025)
• FIGURE 29 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE, 2023-2024 (USD THOUSAND)
• FIGURE 30 AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE, 2022-2024 (USD THOUSAND)
• FIGURE 31 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY REGION, 2022-2024 (USD THOUSAND)
• FIGURE 32 HLA TYPING FOR TRANSPLANT MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
• FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS
• FIGURE 35 HLA TYPING FOR TRANSPLANT MARKET: TRENDS/DISRUPTIONS I MPACTING CUSTOMERS' BUSINESSES
• FIGURE 36 HLA TYPING FOR TRANSPLANT MARKET: FUNDING AND NUMBER OF DEALS, 2019-2023
• FIGURE 37 HLA TYPING FOR TRANSPLANT MARKET: NUMBER OF DEALS, BY KEY PLAYER, 2019-2023
• FIGURE 38 HLA TYPING FOR TRANSPLANT MARKET: VALUE OF DEALS, BY KEY PLAYER, 2019-2023 (USD)
• FIGURE 39 AI USE CASES IN HLA TYPING FOR TRANSPLANT MARKET
• FIGURE 40 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT
• FIGURE 41 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT
• FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET (2020-2024)
• FIGURE 43 MARKET SHARE ANALYSIS OF PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET (2024)
• FIGURE 44 HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 45 HLA TYPING FOR TRANSPLANT MARKET: COMPANY FOOTPRINT
• FIGURE 46 HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 47 EV/EBITDA OF KEY VENDORS
• FIGURE 48 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 49 HLA TYPING FOR TRANSPLANT MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
• FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT
• FIGURE 52 QIAGEN: COMPANY SNAPSHOT
• FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
• FIGURE 54 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
• FIGURE 55 CAREDX, INC.: COMPANY SNAPSHOT
• FIGURE 56 DIASORIN S.P.A.: COMPANY SNAPSHOT
• FIGURE 57 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
• FIGURE 58 EUROBIO SCIENTIFIC: COMPANY SNAPSHOT
• FIGURE 59 PACBIO: COMPANY SNAPSHOT

The global HLA typing for transplant market is projected to reach USD 1.4 billion by 2030 from USD 1.1 billion in 2025, at a CAGR of 6.0% during the forecast period. The growth of the HLA typing market is being propelled by several key factors: the development of sophisticated HLA typing technologies, a rising demand for organ transplantation, strategic government efforts aimed at improving organ donation rates, and an expansion of research initiatives focused on HLA typing methodologies.

By technology, the molecular assays segment accounted for the largest market share in 2024.

The HLA typing for transplant market, by technology, is segmented into non-molecular and molecular assays. In 2024, the molecular assay technologies segment dominated the HLA typing market for transplants, reflecting a significant trend towards the utilization of molecular approaches among end users. This dominance is driven by a concerted emphasis from manufacturers on advancing high-resolution assays within molecular platforms, enhancing the accuracy and reliability of HLA typing for transplantation purposes.

By end user, the independent reference laboratories segment accounted for the largest market share in 2024

The HLA typing for transplant market is segmented based on end users into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2024, independent reference laboratories are projected to dominate the market, driven by a stronger inclination among diagnostic labs to outsource HLA typing services to biotech firms. This shift is facilitated by the advent of high-resolution molecular techniques and the rising number of strategic partnerships between reference laboratories and transplantation centers, enhancing service efficiency and diagnostic precision.

North America accounted for the largest market share, by region, in 2024.

In 2024, North America dominated the HLA typing market for transplant applications, closely followed by Europe. This trend can be attributed to several factors, including the availability of cutting-edge diagnostic technologies, a robust ecosystem of manufacturers, and a well-established healthcare infrastructure. Furthermore, the region is home to leading biotechnology firms that are active in the R&D of novel HLA alleles. Coupled with rising transplantation rates and supportive reimbursement frameworks, these elements significantly contribute to the market's expansion in North America.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-20%, Tier 2-45%, and Tier 3-35%
• By Designation: C-level-35%, Directors-25%, and Others-40%
• By Region: North America-40%, Europe-30%, Asia Pacific-20%, Latin America-5%, and the Middle East & Africa-5%

Some of the prominent players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN (Germany), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Werfen (US), and TBG Biotechnology Corporation (Taiwan).

Research Coverage

This report studies the HLA typing for transplant market based on product& service, technology, transplant type, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes market opportunities and challenges for stakeholders and details the competitive landscape for market leaders. It is with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Rationale to Buy the Report

The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.

This report provides insights into the following pointers:

• Analysis of key drivers ( increasing transplantation rates, growing technological advancements, increasing government initiatives to boost HLA typing services in transplantation) restraints (high cost of molecular test use in HLA typing procedures), opportunities (technological shift from non-molecular serological assay to molecular assay, high growth offered by emerging markets), and challenges (Significant gap between number of organ donors and transplant recipients) influencing the growth of HLA typing for transplant market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the HLA typing for transplant market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the HLA typing for transplant market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the HLA typing for transplant market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key insights from primary experts
    • 2.1.2.4 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 MARKET ESTIMATION APPROACH
    • 2.2.1.1 Company revenue-based market estimation approach top-down approach
    • 2.2.1.2 Procedure-based market estimation bottom-up approach
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HLA TYPING FOR TRANSPLANT MARKET OVERVIEW
• 4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024
• 4.3 HLA TYPING FOR TRANSPLANT MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 (USD MILLION)
• 4.4 HLA TYPING FOR TRANSPLANT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising number of organ donors and transplant procedures
    • 5.2.1.2 Surge in organ failure cases due to increased prevalence of chronic diseases
    • 5.2.1.3 Increasing research activities and rising funding for organ transplantations
    • 5.2.1.4 Growing adoption of HLA typing in personalized medicines
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of HLA typing products
    • 5.2.2.2 Shortage of healthy organs for transplants
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Adoption of NGS and automation for high-throughput needs
    • 5.2.3.2 Use of AI and ML in HLA typing for better accuracy and broader clinical utility
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory complexities across regions
    • 5.2.4.2 Lack of standardization across HLA typing laboratories
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY FRAMEWORK
    • 5.3.1.1 North America
      • 5.3.1.1.1 US
      • 5.3.1.1.2 Canada
    • 5.3.1.2 Europe
      • 5.3.1.2.1 UK
      • 5.3.1.2.2 France
      • 5.3.1.2.3 Germany
    • 5.3.1.3 Asia Pacific
      • 5.3.1.3.1 China
      • 5.3.1.3.2 Japan
      • 5.3.1.3.3 India
    • 5.3.1.4 Latin America
      • 5.3.1.4.1 Brazil
      • 5.3.1.4.2 Mexico
    • 5.3.1.5 Middle East & Africa
  • 5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 RESEARCH & DEVELOPMENT
  • 5.4.2 RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT
  • 5.4.3 MARKETING, SALES, AND DISTRIBUTION, AND AFTERMARKET SERVICE
• 5.5 SUPPLY CHAIN ANALYSIS
  • 5.5.1 PROMINENT COMPANIES
  • 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.5.3 SALES & DISTRIBUTION AGENTS
  • 5.5.4 END USERS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO FOR HS CODE 3822, 2020-2024
  • 5.7.2 EXPORT SCENARIO FOR HS CODE 3822, 2020-2024
• 5.8 PATENT ANALYSIS
  • 5.8.1 LIST OF MAJOR PATENTS/PATENT APPLICATIONS
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE, 2023-2024
  • 5.9.2 AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023-2024
  • 5.9.3 AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE, 2022-2024
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Next-generation sequencing
    • 5.10.1.2 PCR-Sequence-specific oligonucleotide probes
  • 5.10.2 COMPLEMENTARY TECHNOLOGIES
    • 5.10.2.1 Single antigen-based assays
    • 5.10.2.2 Flow cytometry crossmatch
  • 5.10.3 ADJACENT TECHNOLOGIES
    • 5.10.3.1 Bioinformatics software
• 5.11 PORTER'S FIVE FORCE ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 KEY BUYING CRITERIA
• 5.13 KEY CONFERENCES & EVENTS IN 2024-2025
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING HLA TYPING ACCURACY IN TRANSPLANTATION
  • 5.14.2 ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION
  • 5.14.3 WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING
• 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 UNMET NEEDS
• 5.18 IMPACT OF AI/GEN AI ON HLA TYPING FOR TRANSPLANT MARKET
  • 5.18.1 MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR PRE-TRANSPLANT EVALUATION
    • 5.18.1.1 AI use cases in HLA typing for transplant market
    • 5.18.1.2 Key companies implementing AI
  • 5.18.2 FUTURE OF AI IN HLA TYPING FOR TRANSPLANT MARKET
• 5.19 IMPACT OF 2025 US TARIFF ON HLA TYPING FOR TRANSPLANT MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
  • 5.19.4 IMPACT ON COUNTRY/REGION
    • 5.19.4.1 North America
      • 5.19.4.1.1 US
    • 5.19.4.2 Europe
    • 5.19.4.3 Asia Pacific
  • 5.19.5 IMPACT ON END-USE INDUSTRIES

6 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS & CONSUMABLES
  • 6.2.1 AVAILABILITY OF MULTIPLE VARIETIES OF REAGENTS & CONSUMABLES TO DRIVE ADOPTION IN HLA TYPING PHASES
• 6.3 INSTRUMENTS
  • 6.3.1 NEED FOR PRECISE AND RELIABLE HLA MATCHING IN BONE MARROW AND ORGAN TRANSPLANTS TO PROPEL MARKET GROWTH
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 GROWING AUTOMATION AND DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO AID MARKET GROWTH

7 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 MOLECULAR ASSAYS
  • 7.2.1 PCR-BASED MOLECULAR ASSAYS
    • 7.2.1.1 Sequence-specific primer-PCR
      • 7.2.1.1.1 Cost-effectiveness and high accuracy to drive identification of HLA variants at low to intermediate resolutions
    • 7.2.1.2 Sequence-specific oligonucleotide-PCR
      • 7.2.1.2.1 Development and commercialization of innovative sequence-specific oligonucleotide-PCR products to aid segment growth
    • 7.2.1.3 Real-time PCR
      • 7.2.1.3.1 High sensitivity, effective real-time DNA amplification monitoring, and minimal sample need to drive segment
    • 7.2.1.4 Other PCR-based molecular assays
• 7.3 SEQUENCING-BASED MOLECULAR ASSAYS
  • 7.3.1 SANGER SEQUENCING
    • 7.3.1.1 High accuracy and single-base resolution to detect allelic variants and confirm novel or rare alleles
  • 7.3.2 NEXT-GENERATION SEQUENCING
    • 7.3.2.1 Growing reliance on outsourcing in-house analysis to propel demand in tissue typing
  • 7.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS
• 7.4 NON-MOLECULAR ASSAYS
  • 7.4.1 LOWER COSTS AND HIGHER SPECIFICITY TO DRIVE ADOPTION OVER MOLECULAR ASSAYS

8 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DIAGNOSTIC APPLICATIONS
  • 8.2.1 ANTIBODY SCREENING
    • 8.2.1.1 Advancement in pre-transplant compatibility screening with NGS to aid segment growth
  • 8.2.2 CHIMERISM MONITORING
    • 8.2.2.1 Growing trend of personalized transplant medicine for effective post-procedural clinical risk management to fuel adoption
  • 8.2.3 OTHER DIAGNOSTIC APPLICATIONS
• 8.3 RESEARCH APPLICATIONS
  • 8.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS FOR TRANSPLANT DIAGNOSTICS RESEARCH TO FAVOR MARKET GROWTH

9 HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE

• 9.1 INTRODUCTION
• 9.2 SOLID ORGAN TRANSPLANTS
  • 9.2.1 HIGH POPULARITY OF ORGAN DONATION AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET
• 9.3 SOFT-TISSUE TRANSPLANTS
  • 9.3.1 NEED FOR HLA TYPING IN COMPOSITE TISSUE ALLOTRANSPLANTATION TO AID ADOPTION
• 9.4 STEM CELL TRANSPLANTS
  • 9.4.1 EXPANDING DIVERSITY OF DONOR REGISTRIES TO FUEL ADOPTION OF HLA TYPING

10 HLA TYPING FOR TRANSPLANT MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 INDEPENDENT REFERENCE LABORATORIES
  • 10.2.1 ADHERENCE TO QUALITY AND REGULATORY STANDARDS WITH HIGH-QUALITY SERVICES TO DRIVE MARKET GROWTH
• 10.3 HOSPITALS & TRANSPLANT CENTERS
  • 10.3.1 DEVELOPED HEALTHCARE INFRASTRUCTURE AND HIGH SUCCESS RATES IN TRANSPLANT PROCEDURES TO DRIVE MARKET
• 10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
  • 10.4.1 INCREASING COLLABORATIONS TO DEVELOP AND OPTIMIZE HLA TYPING FOR BETTER ACCURACY, SPECIFICITY, AND EFFICIENCY

11 HLA TYPING FOR TRANSPLANT MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate HLA typing for transplant market during forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Rising number of solid organ and hematopoietic stem cell transplants to drive market adoption of HLA typing
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 High donor registration rates and favorable government initiatives to augment market growth
  • 11.3.3 UK
    • 11.3.3.1 Strong healthcare infrastructure and centrally coordinated transplant system to foster growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing adoption for donor-recipient compatibility testing to support market
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing popularity of solid organ donation to drive market
  • 11.3.6 ITALY
    • 11.3.6.1 Supportive government policies and strong healthcare infrastructure to spur market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Presence of leading global manufacturers of HLA typing products to drive market
  • 11.4.3 INDIA
    • 11.4.3.1 Rise in transplantation procedures and use of HLA typing for assessing donor-recipient compatibility to spur market growth
  • 11.4.4 JAPAN
    • 11.4.4.1 Increasing number of solid organ transplantation procedures and rising chronic diseases to favor market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing use of genomic testing and analysis and growing government backing for clinical diagnostics to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Government support and advanced healthcare to drive adoption of NGS HLA typing for better transplant outcomes
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Growing elderly demographic and increasing funding from leading HLA typing manufacturers to propel market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Wide recipient base for organ transplant and rise in medical tourism to fuel market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Improvements in healthcare infrastructure and focus on specialized medical services to augment market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product & service footprint
    • 12.5.5.4 Technology footprint
    • 12.5.5.5 Application footprint
    • 12.5.5.6 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 MAJOR PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services/Solutions offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ILLUMINA, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services/Solutions offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 QIAGEN
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services/Solutions offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 BIO-RAD LABORATORIES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services/Solutions offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services/Solutions offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 CAREDX, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services/Solutions offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches and approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 WERFEN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services/Solutions offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches
      • 13.1.7.3.2 Deals
  • 13.1.8 DIASORIN S.P.A.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services/Solutions offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product approvals
  • 13.1.9 TBG BIOTECHNOLOGY CORP.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services/Solutions offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 FUJIREBIO
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services/Solutions offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 BECTON, DICKINSON AND COMPANY
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services/Solutions offered
  • 13.1.12 EUROBIO SCIENTIFIC
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services/Solutions offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches and approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 PACBIO
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services/Solutions offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product approvals and updates
      • 13.1.13.3.2 Deals
  • 13.1.14 BAG DIAGNOSTICS GMBH
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services/Solutions offered
  • 13.1.15 CREATIVE BIOLABS
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services/Solutions offered
• 13.2 OTHER PLAYERS
  • 13.2.1 HISTOGENETICS LLC
  • 13.2.2 SCISCO GENETICS, INC.
  • 13.2.3 INNO-TRAIN DIAGNOSTIK GMBH
  • 13.2.4 BIONOBIS
  • 13.2.5 TAKARA BIO INC.
  • 13.2.6 KRISHGEN BIOSYSTEMS
  • 13.2.7 SCIENCELL RESEARCH LABORATORIES, INC.
  • 13.2.8 PROIMMUNE LTD.
  • 13.2.9 ALPHA BIOTECH LIMITED
  • 13.2.10 BIOFORTUNA LIMITED

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS